Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Combining finasteride and terazosin can cause severe allergic reactions.

Tiny particles carrying roxithromycin can effectively target and deliver the drug to hair follicles without irritation.

This study reports that ritlecitinib was prescribed to a diverse group of patients, including adolescents and adults with and without prior treatment for Alopecia Areata, in the first three months after FDA approval, potentially expanding care options for this condition.

This meta-analysis found that deuruxolitinib significantly improved hair regrowth and patient satisfaction in those with moderate to severe alopecia areata compared to placebo, though it was associated with manageable side effects such as elevated creatinine kinase levels, headaches, and acne, especially at higher doses.

In this study, ritlecitinib showed sustained effectiveness and a favorable safety profile in treating alopecia areata in patients aged 12 and older over 24 months, with improvements observed in hair and eyebrow regrowth and patient satisfaction.

Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.

This reference compilation details potential adverse skin reactions and other side effects associated with the antihypertensive drug Quinazil, including rare cases of skin angioedema and other dermatological reactions.

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.

In this rodent model study, the researchers reported that using low-intensity focused ultrasound with phenytoin enhanced its anti-epileptic efficacy by disrupting plasma protein binding in a region-specific manner, reducing seizure frequency and duration.

The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.

This study evaluates the efficacy and safety of a higher dose (100-mg) of ritlecitinib for treating severe alopecia areata, comparing it to external and synthetic placebo control groups.

In this Italian retrospective study, ritlecitinib 50 mg/day showed effectiveness and good tolerability for treating severe alopecia areata over 24 weeks, achieving significant hair regrowth particularly in adolescents, as well as improvements in eyebrows, eyelashes, nails, and quality of life, with mostly mild adverse effects.

This review discusses the approval of deuruxolitinib, an oral JAK inhibitor, by the FDA in July 2024 for treating severe alopecia areata in adults, highlighting its role as the third approved oral treatment option alongside baricitinib and ritlecitinib.

This study reports that JAK inhibitors were effective in inducing remission in ulcerative colitis patients and presented an acceptable safety profile with a range of manageable side effects.

Teriflunomide can cause hair thinning.

This report details a case of extensive leukotrichia induced by dasatinib in a patient with refractory chronic myelogenous leukemia.

In this study, pioglitazone treatment in patients with lichen planopilaris showed limited success, with significant improvement seen in only a minority of cases.

This article describes a case of hypertrichosis potentially induced by using efalizumab but provides no new clinical study results.

Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.

This study describes that 65% of patients receiving imatinib mesylate in a patient assistance program experienced skin hypopigmentation, primarily in ethnically Chinese individuals, suggesting variability across populations.

This case report highlights a 33-year-old female with systemic lupus erythematosus and refractory alopecia who experienced significant hair regrowth after treatment with tofacitinib, maintained even after glucocorticoid tapering over two years.

In this case report, a woman with Graham-Little-Piccardi-Lassueur Syndrome and hidradenitis suppurativa showed significant improvements in both conditions after six months of treatment with tofacitinib, a Janus Kinase inhibitor, with no recurrence or adverse events noted during a two-year follow-up.

This case study reports generalized keratosis pilaris as a rare cutaneous side effect of nilotinib in a 40-year-old woman with chronic myeloid leukemia, highlighting the need for awareness among physicians.

Olanzapine reduces stress-related anxiety in rats when given acutely.

This case report suggests an association between the use of Sitagliptin, a DPP-4 inhibitor, and the development of alopecia universalis in a diabetic patient.

This study observed that adding simvastatin to ongoing metformin treatment reduced certain androgen levels in women with non-classic congenital adrenal hyperplasia and abnormal glucose metabolism, suggesting a potential therapeutic benefit.

Finasteride interacts with terazosin, but not doxazosin; caution needed.

This study found that the combination of cyproterone acetate and ethinyl estradiol improved hirsutism and acne in women, with SH 8.1041 showing significant results and both treatments being generally well-tolerated.

In this study, short-term treatment with lovastatin showed no effect on symptom severity, prostate volume, or PSA levels in men with prostatic enlargement from presumed benign prostatic hyperplasia.

Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.